

XVIVO Perfusion – Consensus estimates Q2 2025

Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.

Number of contributors: 6 (all of which have been updated or confirmed before the report)

KPI (MSEK, unless otherwise specified)	Q2 2025E
Net sales	224
Organic growth in local currency (%)	11.60
Gross profit	166
EBITDA	46.5
EBIT	28.7
Net profit	17.8
Earnings per share (SEK)	0.55

XVIVO Perfusion's Q2 report will be released on Friday, 11 July 2025 at 07.30 CEST.